Models Predict Positive Public Health Effects for RTS,S Vaccine — with Qualifications

The combined results of four models suggest high cost-effectiveness of the malaria vaccine over 15 years in areas with parasite prevalence >10%.

Phase III clinical trials of RTS,S/AS01 have shown modest vaccine efficacy against clinical malaria after three doses — 20% in infants (6–12 weeks) and 35% in children (5–17 months) during 32 months follow-up, with efficacy waning over time (NEJM JW Infect Dis Jun 2015 and Lancet 2015; 386:31). Given these results, should this vaccine be used and, if so, in which populations?

To examine the vaccine's cost-effectiveness and public health effects, researchers used estimates and predictions from four modeling groups. They quantified the potential number of cases and deaths averted over 15 years if vaccination is implemented, with a three- or four-dose vaccine schedule, for populations with parasite prevalence in 2- to 10-year-olds between 3% an…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Models Predict Positive Public Health Effects for RTS,S Vaccine — with Qualifications

Topics

Reviewing Author